Economical diagnostic system for accurate and rapid diagnosis and prevention of rare incurable diseases such as cancer and degenerative brain diseases
  • · Started to apply the disease marker analysis technology, which is a proprietary technology owned by GlycoMetrix in the US.
  • · Based on the proprietary technology, established a fast and accurate early cancer diagnosis system and DB Signature for the first time in the world
  • · Early diagnosis system for various cancers including ovarian cancer, breast cancer, and pancreatic cancer
  • · Currently researching and developing early diagnosis techniques for major degenerative brain diseases (e.g. Parkinson’s disease, and Alzheimer’s)

It is possible to quickly and accurately diagnose cancer by
securing and processing glycan changes in the blood through
database signature big data.

It is a new paradigm of the glycomics diagnosis method that can improve the
accuracy of diagnosis while eliminating the high level of experience, skills
and long time required to reach the final diagnosis which were the previous
limitations of the existing genomics-proteomics-based diagnosis technology.

Establishment of DB for each cancer stage and
implementation of specific diagnosis system

It minimizes misdiagnosis, and ensure
accurate diagnosis reproducibility